Trials / Unknown
UnknownNCT01170338
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Newark Beth Israel Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Varenicline 100 mg by mouth twice daily | this is an active drug to help smoking cessation |
| DRUG | control | this is the placebo that will help us maintain a blinded study |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-07-01
- First posted
- 2010-07-27
- Last updated
- 2010-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01170338. Inclusion in this directory is not an endorsement.